EU Accepts Sanofi Concessions to End Vaccine Antitrust Probe

The agreement addresses concerns that Sanofi’s promotional communications may have affected competition with a rival influenza vaccine produced by Australia’s CSL, according to a report by The Wall Street Journal.

The European Commission, which oversees competition enforcement across the 27-member European Union, determined that Sanofi’s proposed measures were sufficient to address the potential consequences of its earlier marketing statements.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Add as Preferred Source

Under the resolution, the company’s commitments will become legally binding, the commission said, as reported by The Wall Street Journal.

The decision follows an investigation opened in June to examine whether Sanofi’s marketing practices violated EU competition regulations.

Read more: EU Opens Antitrust Investigation Into Sanofi Over Flu Vaccine Marketing Campaign

The case centered on the potential competitive impact of statements made about CSL’s influenza vaccine. Sanofi offered to take corrective action aimed at addressing any effects those communications may have had on its competitor.

The commission’s acceptance of those measures provides a regulatory resolution without requiring the investigation to proceed further under the commitments process.

The settlement does not constitute a formal finding that Sanofi violated EU competition law. The company avoids an immediate antitrust penalty but remains subject to enforcement if it fails to comply with the agreed measures, according to the European Commission’s published decision.

The commitments include restrictions on certain promotional claims in France and Germany through March 2030, along with public clarifications about the competing vaccines.